Globenewswireยท2025-10-15 14:03Core Insights - Sonnet BioTherapeutics is collaborating with Spanios to conduct a non-clinical study using patient-derived tumoroid platforms to evaluate the effect of SON-1010 in soft tissue sarcoma, aiming to accelerate treatment development for rare cancers [1][2]. Company Overview - Sonnet BioTherapeutics is an oncology-focused biotechnology company that develops targeted biologic drugs using its proprietary FHAB platform, which utilizes a fully human single chain antibody fragment for targeted delivery to tumor microenvironments [3]. - Spanios is dedicated to accelerating the discovery and development of oncology drugs for rare cancers, utilizing its COMPASS platform to recreate human solid tumors and their microenvironments, thus improving predictive accuracy in preclinical research [4]. Technology and Methodology - The study employs Spanios' COMPASS platform, which replicates the tumor microenvironment with physiological oxygenation, enhancing the understanding of SON-1010's efficacy against cancer cells [2]. - The innovative approach of using patient-derived tumoroids allows for more accurate predictions regarding the clinical performance of SON-1010 therapy compared to traditional animal models [2][4]. Leadership Insights - Raghu Rao, Interim CEO of Sonnet, emphasized the potential of the tumoroid platform for rapid evaluation of new drugs across various solid tumors [3]. - Bhuvanesh Dave, Co-Founder and CEO of Spanios, expressed excitement about the collaboration, highlighting the combined expertise aimed at advancing therapeutic research for solid tumors [4].